The myeloproliferative neoplasms (MPN) of essential thrombocythemia (ET) and primary myelofibrosis (PMF) can be broadly molecularly characterized into four main groups according to the presence of acquired mutations in JAK2, CALR or MPL genes (all resulting in cytokine-independent proliferative signaling) or those without these mutations, termed “triple negative” (Grabek et al., 2020). Of these groups, MPL mutations are the less common, occurring in approximately 5-10 % of MPN patients and which result in a particular phenotype (Alvarez-Larran et al., 2018). The majority of MPL mutations occur in exon 10 that encodes the transmembrane domain although sporadic mutations elsewhere in the gene have been documented. Within exon 10, the mutational hotspot is the codon for Tryptophan at position W515 (Ma et al., 2011). A review was performed on the frequency and type of MPL exon 10 mutations in an Irish population of patients with suspected MPN in order to inform future screening strategies.
An audit was performed on all requests for MPL exon 10 mutations at a referral center for molecular diagnosis of hematological malignancies over a three-year period from January 2018 to December 2020 inclusive. From this period, 383 requests were received in patients previously characterized as JAK2 V617F and CALR exon 9 mutation undetected. MPL exon 10 mutations were detected by a targeted next-generation sequencing (NGS) methodology unchanged throughout the audit period. A total of 14 (3.7 %) of patients had evidence of a W515 mutation comprising MPL W515L, W515K, W515S and W515A mutations (Figure 1(Fig. 1)). Absence of clinical details provided means ascribing mutations to either an ET or PMF phenotype is not possible.
These findings are largely in keeping with those from other European populations in respect to both frequency and spectrum of MPL exon 10 mutations with the W515L being the most prevalent (Boyd et al., 2010; Cheng Pettersson et al., 2017; Schnittger et al., 2009). An improvement in mutation identification strategy would be to expand NGS coverage enabling routine screening for non-canonical mutations elsewhere in the coding region of MPL (Acha et al., 2019). This brief survey provides a platform for continual refinement of the molecular diagnostic algorithm for MPN patients.
The authors declare that they have no conflicts of interest.
Figure 1: Distribution of MPL W515 mutations in an Irish population of patients with a suspected myeloproliferative neoplasm
[*] Corresponding Author:
Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, eMail: email@example.com